NR 326 Mental Health Nursing Final Exam Prep Document |
2026/2027 Edition | 250 Verified Questions
NR 326 Mental Health Nursing Final Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document contains 250 verified questions for the NR 326
Mental Health Nursing final exam, covering all major content areas. Each question includes detailed
rationales to reinforce understanding and critical thinking. Designed for the 2026/2027 academic year,
this resource ensures students are fully prepared to achieve a top grade. The content aligns with current
nursing standards and evidence-based practices.
Abstract:
The NR 326 Mental Health Nursing Final Exam Preparation Document for the 2026/2027 academic year offers a
rigorous review of essential mental health nursing concepts. With 250 meticulously verified questions, this
resource covers therapeutic communication, psychopharmacology, mood disorders, anxiety disorders, psychotic
disorders, and legal-ethical considerations. Each question is accompanied by detailed rationales that explain
correct and incorrect answers, promoting deep learning and clinical reasoning. The content is aligned with the
latest DSM-5-TR guidelines and NCLEX test plans, ensuring relevance and accuracy. This document is designed to
help nursing students achieve a thorough understanding of mental health nursing and excel in their final exam. By
integrating theoretical knowledge with practical application, it prepares students for both the exam and real-world
clinical practice. The comprehensive coverage and high-quality rationales make this an indispensable tool for
success.
Content Area Overview:
Content Area Questions Key Topics Weight
Therapeutic Communication & 1-40 Active listening, empathy, boundaries, 16%
Nurse-Patient Relationship transference, countertransference
Psychopharmacology 41-80 Antidepressants, antipsychotics, mood 16%
stabilizers, anxiolytics, side effects
Mood Disorders & Suicide 81-120 Major depressive disorder, bipolar disorder, 16%
suicide risk assessment, interventions
Anxiety, Trauma, & 121-160 Generalized anxiety, PTSD, OCD, panic 16%
Stressor-Related Disorders disorder, coping mechanisms
Psychotic Disorders & 161-200 Positive/negative symptoms, antipsychotic 16%
Schizophrenia medications, nursing interventions
Legal & Ethical Issues 201-250 Involuntary commitment, patient rights, 20%
confidentiality, informed consent
Page 1
,Q1. A client with major depressive disorder has been on fluoxetine 40 mg daily for 6 weeks with
minimal improvement. The provider considers augmentation. Which augmentation strategy is
supported by the latest evidence as most effective for treatment-resistant depression?
A. Adding aripiprazole 2-5 mg/day
B. Switching to venlafaxine 225 mg/day
C. Adding bupropion 150 mg/day
D. Augmenting with lithium 600 mg/day
Correct Answer: A. Adding aripiprazole 2-5 mg/day
Rationale: Aripiprazole (an atypical antipsychotic) is FDA-approved for adjunctive treatment of major
depressive disorder and has strong evidence for efficacy in treatment-resistant depression. Bupropion
augmentation is common but less supported by rigorous trials. Lithium augmentation is effective but used
less often due to monitoring requirements. Venlafaxine is a switch strategy, not augmentation.
Why Wrong:
B - Switching to venlafaxine is a different strategy (not augmentation) and may be less effective than
adding aripiprazole.
C - Bupropion augmentation is commonly used but has weaker evidence compared to aripiprazole
for treatment-resistant depression.
D - Lithium augmentation is effective but requires frequent serum monitoring and is not first-line
due to side effect profile.
Reference: Stahl, S. M. (2025). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5
Q2. A client with borderline personality disorder frequently engages in self-harm by cutting. During
a therapy session, the client states, 'You're the only one who understands me.' Which nursing
response best reflects a therapeutic boundary while maintaining rapport?
A. I appreciate that you feel that way, but it's important for you to develop trust with the whole team.
B. I understand you feel close to me, but our relationship is professional. Let's focus on your coping
strategies.
C. You seem to be idealizing me. That's a common pattern in your disorder.
D. It's not healthy to depend on just one person. You need to spread out your trust.
Correct Answer: B. I understand you feel close to me, but our relationship is professional. Let's
focus on your coping strategies.
Rationale: Option B validates the client's feeling while clearly re-establishing the professional boundary
and redirecting to therapeutic work. Option A, though somewhat appropriate, may invalidate the client's
expression. Option C is confrontational and uses labeling. Option D is dismissive and prescriptive.
Why Wrong:
A - This response may be perceived as rejecting and does not explicitly maintain the professional
boundary.
C - Labeling the client's behavior as 'idealizing' can be experienced as judgmental and damage the
therapeutic alliance.
D - This is a directive statement that fails to validate the client's feelings and may increase feelings
of abandonment.
Reference: Varcarolis, E. M. (2026). Foundations of Psychiatric Mental Health Nursing, 9th Ed., Ch. 11
Page 2
,Q3. A client with schizophrenia is started on clozapine after failing two other antipsychotics. Which
combination of baseline and ongoing monitoring is essential to prevent life-threatening adverse
effects?
A. Baseline ECG and echocardiogram; monthly troponin levels
B. Baseline absolute neutrophil count (ANC) and weekly ANC for first 6 months
C. Baseline serum creatinine and BUN; monthly urine protein
D. Baseline liver function tests and monthly ALT/AST
Correct Answer: B. Baseline absolute neutrophil count (ANC) and weekly ANC for first 6 months
Rationale: Clozapine carries a risk of agranulocytosis, requiring mandatory baseline and weekly ANC
monitoring for the first 6 months, then every 2 weeks thereafter. ECG monitoring is for QTc prolongation
but not the primary life-threatening risk. Renal and hepatic monitoring are not specific to clozapine's
most dangerous adverse effect.
Why Wrong:
A - ECG and troponin are not the primary monitoring for clozapine; the main risk is agranulocytosis,
not cardiotoxicity.
C - Renal monitoring is not required for clozapine; it is more relevant for lithium toxicity.
D - Liver function monitoring is not the priority; agranulocytosis is the most serious and requires
ANC monitoring.
Reference: Lehne, R. A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 29
Q4. A client is admitted after a suicide attempt by overdose. The client is now medically stable but
refuses to speak and avoids eye contact. Which nursing intervention is most appropriate initially?
A. Sit quietly with the client without demanding conversation.
B. Encourage the client to verbalize feelings about the attempt.
C. Inform the client that silence will delay discharge.
D. Ask direct closed-ended questions to obtain information.
Correct Answer: A. Sit quietly with the client without demanding conversation.
Rationale: A non-demanding presence conveys acceptance and safety, allowing the client to regain
control. Pressuring verbalization (B) may increase anxiety. Threats (C) are coercive. Closed-ended
questions (D) may feel intrusive and are less therapeutic in early engagement.
Why Wrong:
B - Forcing verbalization can increase anxiety and resistance; the client is not ready to discuss
feelings.
C - Using discharge as leverage is manipulative and damages trust.
D - Closed-ended questions can feel interrogative and inhibit open communication.
Reference: American Psychiatric Association (2025). Practice Guidelines for the Assessment and
Treatment of Patients with Suicidal Behaviors
Page 3
, Q5. A client with bipolar I disorder is experiencing a manic episode with psychotic features. The
client has not slept in 3 days, is talking rapidly, and believes they are a prophet. Which medication
regimen is most appropriate for acute management?
A. Lithium carbonate 900 mg/day monotherapy
B. Valproic acid 1000 mg/day plus lorazepam 2 mg IM as needed
C. Olanzapine 10 mg IM plus valproic acid 1000 mg/day
D. Carbamazepine 800 mg/day monotherapy
Correct Answer: C. Olanzapine 10 mg IM plus valproic acid 1000 mg/day
Rationale: In acute mania with psychosis, guidelines recommend combination therapy with an atypical
antipsychotic (e.g., olanzapine) and a mood stabilizer (e.g., valproic acid). IM olanzapine provides rapid
calming. Lithium monotherapy has a slower onset and is less effective for severe mania. Valproic acid
plus lorazepam lacks antipsychotic coverage. Carbamazepine monotherapy is not first-line.
Why Wrong:
A - Lithium monotherapy has a slow onset (1-2 weeks) and is insufficient for acute severe mania
with psychosis.
B - Lorazepam does not treat psychotic symptoms; an antipsychotic is needed.
D - Carbamazepine is not first-line for acute mania and has many drug interactions.
Reference: APA Practice Guideline for the Treatment of Patients with Bipolar Disorder, 3rd Ed. (2025)
Q6. A client with generalized anxiety disorder has been on sertraline 100 mg/day for 8 weeks with
partial response. The client continues to experience excessive worry and muscle tension. Which next
step is supported by current evidence?
A. Increase sertraline to 200 mg/day
B. Add buspirone 15 mg twice daily
C. Switch to paroxetine 40 mg/day
D. Augment with pregabalin 150 mg twice daily
Correct Answer: A. Increase sertraline to 200 mg/day
Rationale: For partial response to an SSRI, increasing to the maximum therapeutic dose (sertraline 200
mg/day) is recommended before switching or augmenting. Buspirone is less effective for GAD. Paroxetine
is another SSRI but switching is not first-line. Pregabalin is not FDA-approved for GAD and has abuse
potential.
Why Wrong:
B - Buspirone has modest efficacy for GAD and is not typically used as augmentation after SSRI
partial response.
C - Switching to another SSRI is an option after dose optimization, but increasing the current dose is
first.
D - Pregabalin is not FDA-approved for GAD in the US; it is used off-label but with limited
evidence.
Reference: Bandelow, B., et al. (2024). World Federation of Societies of Biological Psychiatry Guidelines
for Anxiety Disorders
Page 4
2026/2027 Edition | 250 Verified Questions
NR 326 Mental Health Nursing Final Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document contains 250 verified questions for the NR 326
Mental Health Nursing final exam, covering all major content areas. Each question includes detailed
rationales to reinforce understanding and critical thinking. Designed for the 2026/2027 academic year,
this resource ensures students are fully prepared to achieve a top grade. The content aligns with current
nursing standards and evidence-based practices.
Abstract:
The NR 326 Mental Health Nursing Final Exam Preparation Document for the 2026/2027 academic year offers a
rigorous review of essential mental health nursing concepts. With 250 meticulously verified questions, this
resource covers therapeutic communication, psychopharmacology, mood disorders, anxiety disorders, psychotic
disorders, and legal-ethical considerations. Each question is accompanied by detailed rationales that explain
correct and incorrect answers, promoting deep learning and clinical reasoning. The content is aligned with the
latest DSM-5-TR guidelines and NCLEX test plans, ensuring relevance and accuracy. This document is designed to
help nursing students achieve a thorough understanding of mental health nursing and excel in their final exam. By
integrating theoretical knowledge with practical application, it prepares students for both the exam and real-world
clinical practice. The comprehensive coverage and high-quality rationales make this an indispensable tool for
success.
Content Area Overview:
Content Area Questions Key Topics Weight
Therapeutic Communication & 1-40 Active listening, empathy, boundaries, 16%
Nurse-Patient Relationship transference, countertransference
Psychopharmacology 41-80 Antidepressants, antipsychotics, mood 16%
stabilizers, anxiolytics, side effects
Mood Disorders & Suicide 81-120 Major depressive disorder, bipolar disorder, 16%
suicide risk assessment, interventions
Anxiety, Trauma, & 121-160 Generalized anxiety, PTSD, OCD, panic 16%
Stressor-Related Disorders disorder, coping mechanisms
Psychotic Disorders & 161-200 Positive/negative symptoms, antipsychotic 16%
Schizophrenia medications, nursing interventions
Legal & Ethical Issues 201-250 Involuntary commitment, patient rights, 20%
confidentiality, informed consent
Page 1
,Q1. A client with major depressive disorder has been on fluoxetine 40 mg daily for 6 weeks with
minimal improvement. The provider considers augmentation. Which augmentation strategy is
supported by the latest evidence as most effective for treatment-resistant depression?
A. Adding aripiprazole 2-5 mg/day
B. Switching to venlafaxine 225 mg/day
C. Adding bupropion 150 mg/day
D. Augmenting with lithium 600 mg/day
Correct Answer: A. Adding aripiprazole 2-5 mg/day
Rationale: Aripiprazole (an atypical antipsychotic) is FDA-approved for adjunctive treatment of major
depressive disorder and has strong evidence for efficacy in treatment-resistant depression. Bupropion
augmentation is common but less supported by rigorous trials. Lithium augmentation is effective but used
less often due to monitoring requirements. Venlafaxine is a switch strategy, not augmentation.
Why Wrong:
B - Switching to venlafaxine is a different strategy (not augmentation) and may be less effective than
adding aripiprazole.
C - Bupropion augmentation is commonly used but has weaker evidence compared to aripiprazole
for treatment-resistant depression.
D - Lithium augmentation is effective but requires frequent serum monitoring and is not first-line
due to side effect profile.
Reference: Stahl, S. M. (2025). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5
Q2. A client with borderline personality disorder frequently engages in self-harm by cutting. During
a therapy session, the client states, 'You're the only one who understands me.' Which nursing
response best reflects a therapeutic boundary while maintaining rapport?
A. I appreciate that you feel that way, but it's important for you to develop trust with the whole team.
B. I understand you feel close to me, but our relationship is professional. Let's focus on your coping
strategies.
C. You seem to be idealizing me. That's a common pattern in your disorder.
D. It's not healthy to depend on just one person. You need to spread out your trust.
Correct Answer: B. I understand you feel close to me, but our relationship is professional. Let's
focus on your coping strategies.
Rationale: Option B validates the client's feeling while clearly re-establishing the professional boundary
and redirecting to therapeutic work. Option A, though somewhat appropriate, may invalidate the client's
expression. Option C is confrontational and uses labeling. Option D is dismissive and prescriptive.
Why Wrong:
A - This response may be perceived as rejecting and does not explicitly maintain the professional
boundary.
C - Labeling the client's behavior as 'idealizing' can be experienced as judgmental and damage the
therapeutic alliance.
D - This is a directive statement that fails to validate the client's feelings and may increase feelings
of abandonment.
Reference: Varcarolis, E. M. (2026). Foundations of Psychiatric Mental Health Nursing, 9th Ed., Ch. 11
Page 2
,Q3. A client with schizophrenia is started on clozapine after failing two other antipsychotics. Which
combination of baseline and ongoing monitoring is essential to prevent life-threatening adverse
effects?
A. Baseline ECG and echocardiogram; monthly troponin levels
B. Baseline absolute neutrophil count (ANC) and weekly ANC for first 6 months
C. Baseline serum creatinine and BUN; monthly urine protein
D. Baseline liver function tests and monthly ALT/AST
Correct Answer: B. Baseline absolute neutrophil count (ANC) and weekly ANC for first 6 months
Rationale: Clozapine carries a risk of agranulocytosis, requiring mandatory baseline and weekly ANC
monitoring for the first 6 months, then every 2 weeks thereafter. ECG monitoring is for QTc prolongation
but not the primary life-threatening risk. Renal and hepatic monitoring are not specific to clozapine's
most dangerous adverse effect.
Why Wrong:
A - ECG and troponin are not the primary monitoring for clozapine; the main risk is agranulocytosis,
not cardiotoxicity.
C - Renal monitoring is not required for clozapine; it is more relevant for lithium toxicity.
D - Liver function monitoring is not the priority; agranulocytosis is the most serious and requires
ANC monitoring.
Reference: Lehne, R. A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 29
Q4. A client is admitted after a suicide attempt by overdose. The client is now medically stable but
refuses to speak and avoids eye contact. Which nursing intervention is most appropriate initially?
A. Sit quietly with the client without demanding conversation.
B. Encourage the client to verbalize feelings about the attempt.
C. Inform the client that silence will delay discharge.
D. Ask direct closed-ended questions to obtain information.
Correct Answer: A. Sit quietly with the client without demanding conversation.
Rationale: A non-demanding presence conveys acceptance and safety, allowing the client to regain
control. Pressuring verbalization (B) may increase anxiety. Threats (C) are coercive. Closed-ended
questions (D) may feel intrusive and are less therapeutic in early engagement.
Why Wrong:
B - Forcing verbalization can increase anxiety and resistance; the client is not ready to discuss
feelings.
C - Using discharge as leverage is manipulative and damages trust.
D - Closed-ended questions can feel interrogative and inhibit open communication.
Reference: American Psychiatric Association (2025). Practice Guidelines for the Assessment and
Treatment of Patients with Suicidal Behaviors
Page 3
, Q5. A client with bipolar I disorder is experiencing a manic episode with psychotic features. The
client has not slept in 3 days, is talking rapidly, and believes they are a prophet. Which medication
regimen is most appropriate for acute management?
A. Lithium carbonate 900 mg/day monotherapy
B. Valproic acid 1000 mg/day plus lorazepam 2 mg IM as needed
C. Olanzapine 10 mg IM plus valproic acid 1000 mg/day
D. Carbamazepine 800 mg/day monotherapy
Correct Answer: C. Olanzapine 10 mg IM plus valproic acid 1000 mg/day
Rationale: In acute mania with psychosis, guidelines recommend combination therapy with an atypical
antipsychotic (e.g., olanzapine) and a mood stabilizer (e.g., valproic acid). IM olanzapine provides rapid
calming. Lithium monotherapy has a slower onset and is less effective for severe mania. Valproic acid
plus lorazepam lacks antipsychotic coverage. Carbamazepine monotherapy is not first-line.
Why Wrong:
A - Lithium monotherapy has a slow onset (1-2 weeks) and is insufficient for acute severe mania
with psychosis.
B - Lorazepam does not treat psychotic symptoms; an antipsychotic is needed.
D - Carbamazepine is not first-line for acute mania and has many drug interactions.
Reference: APA Practice Guideline for the Treatment of Patients with Bipolar Disorder, 3rd Ed. (2025)
Q6. A client with generalized anxiety disorder has been on sertraline 100 mg/day for 8 weeks with
partial response. The client continues to experience excessive worry and muscle tension. Which next
step is supported by current evidence?
A. Increase sertraline to 200 mg/day
B. Add buspirone 15 mg twice daily
C. Switch to paroxetine 40 mg/day
D. Augment with pregabalin 150 mg twice daily
Correct Answer: A. Increase sertraline to 200 mg/day
Rationale: For partial response to an SSRI, increasing to the maximum therapeutic dose (sertraline 200
mg/day) is recommended before switching or augmenting. Buspirone is less effective for GAD. Paroxetine
is another SSRI but switching is not first-line. Pregabalin is not FDA-approved for GAD and has abuse
potential.
Why Wrong:
B - Buspirone has modest efficacy for GAD and is not typically used as augmentation after SSRI
partial response.
C - Switching to another SSRI is an option after dose optimization, but increasing the current dose is
first.
D - Pregabalin is not FDA-approved for GAD in the US; it is used off-label but with limited
evidence.
Reference: Bandelow, B., et al. (2024). World Federation of Societies of Biological Psychiatry Guidelines
for Anxiety Disorders
Page 4
